GW Pharmaceuticals
GW Pharmaceuticals[edit | edit source]
GW Pharmaceuticals is a biopharmaceutical company known for its pioneering work in the development of cannabis-based medicines. Founded in 1998, the company is headquartered in Cambridge, United Kingdom. GW Pharmaceuticals is renowned for its focus on the research, development, and commercialization of cannabinoid prescription medicines using botanical extracts derived from the Cannabis sativa plant.
History[edit | edit source]
GW Pharmaceuticals was established by Dr. Geoffrey Guy and Dr. Brian Whittle with the aim of exploring the therapeutic potential of cannabinoids. The company has since become a leader in the field of cannabinoid science, conducting extensive research and clinical trials to develop innovative treatments for a variety of medical conditions.
Products[edit | edit source]
GW Pharmaceuticals is best known for its development of Epidiolex, a cannabidiol (CBD) oral solution approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with two rare and severe forms of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. Epidiolex was the first cannabis-derived medication to receive FDA approval.
Another notable product developed by GW Pharmaceuticals is Sativex, a mouth spray containing a combination of tetrahydrocannabinol (THC) and CBD. Sativex is approved in several countries for the treatment of spasticity due to multiple sclerosis.
Research and Development[edit | edit source]
GW Pharmaceuticals has a robust research and development program focused on exploring the potential of cannabinoids in treating a wide range of medical conditions. The company conducts clinical trials to evaluate the efficacy and safety of its products in various therapeutic areas, including neurology, oncology, and psychiatry.
Acquisition[edit | edit source]
In 2021, GW Pharmaceuticals was acquired by Jazz Pharmaceuticals, a global biopharmaceutical company, in a deal valued at approximately $7.2 billion. This acquisition has allowed GW Pharmaceuticals to expand its reach and continue its research into cannabinoid-based therapies under the umbrella of Jazz Pharmaceuticals.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
